P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Exclusion Criteria

• •Has inadequate venous access and/or contraindications to leukapheresis
• •Has an active second malignancy in addition to mCRPC or SGC, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
• •Has a history of or active autoimmune disease
• •Has a history of significant central nervous system (CNS) disease, such as stroke or epilepsy
• •Has an active systemic (viral, bacterial or fungal) infection
• •Has received anti-cancer medications (excluding GnRH targeted therapies) within 2 weeks of the time of initiating conditioning chemotherapy
• •Has received immunosuppressive medications (including anti-cancer medications) within 2 weeks of initiating leukapheresis and/or expected to require them while enrolled in the study
• •Has received systemic corticosteroid therapy within 2 weeks of either the required leukapheresis or is expected to require it during the course of the study
• •Has CNS metastases or symptomatic CNS involvement
• •Has a history of significant ocular disease
• •Has a history of significant liver disease or active liver disease
• •Has liver metastases (\<5 lesions and maximum diameter \</= 2.5 cm permitted)
• •Has a history of or known predisposition to HLH or MAS